Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Astellas’ Gastric Cancer Drug Vyloy Now Available in Japan
Astellas Pharma on June 12 rolled out its first-in-class anti-Claudin 18.2 (CLDN18.2) monoclonal antibody Vyloy (zolbetuximab) in Japan for the treatment of CLDN18.2-positive, unresectable, advanced or relapsed gastric cancer.Vyloy is designed to induce cancer cell death by activating two distinct…
To read the full story
Related Article
BUSINESS
- Sarclisa SC Can Meet Patient, Healthcare Worker Needs: Specialist
September 1, 2026
- Merck KGaA to Consolidate Japan Life Science Labs at Haneda Hub
September 1, 2026
- FDA Approves Takeda’s PV Drug Mimrylo
September 1, 2026
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…